2 recruiting. 2 Phase 3.
| Phase | Trials | Status |
|---|---|---|
| Phase 3 | 2 | Recruiting 2 |
Follow Whole-Brain Radiotherapy: new trials by email Literature Review of Whole-Brain Radiotherapy trials Research Report on Whole-Brain Radiotherapy
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| Bevacizumab Plus FSRT Versus Hippocampus-Avoidant WBRT in Lung Adenocarcinoma With Extensive Brain Metastases FSRT, HA-WBRT-SIB, Bevacizumab - Lung Adenocarcinoma, Brain Metastases | Phase 3 | Recruiting | Sun Yat-sen University | 220 | 2026-03-20 | 2026-04-06 |
| Anlotinib Plus Whole-Brain Radiotherapy for Brain Metastases in SCLC Patients. Anlotinib, Whole-brain Radiotherapy - Whole-Brain Radiotherapy | Phase 3 | Recruiting | Cancer Institute and Hospital, Chinese Academy of Medical Sciences | 134 | 2025-08-29 | 2026-03-02 |
Adenocarcinoma of Lung (1) · Brain Neoplasms (1)
Adenocarcinoma (1) · Brain Diseases (1) · Carcinoma (1) · Central Nervous System Diseases (1) · Central Nervous System Neoplasms (1) · Lung Neoplasms (1) · Neoplasms (1) · Neoplasms by Histologic Type (1) · Neoplasms by Site (1) · Neoplasms, Glandular and Epithelial (1) · Nervous System Diseases (1) · Nervous System Neoplasms (1) · Respiratory Tract Neoplasms (1) · Thoracic Neoplasms (1)
Bevacizumab (1) · anlotinib (1)
Cancer Institute and Hospital, Chinese Academy of Medical Sciences (1) · Sun Yat-sen University (1)
China (2)
Lei Deng, MD (1)
PMID 15254054, PMID 16757720, PMID 16856022, PMID 19801201, PMID 23814264, PMID 25349290, PMID 27458945, PMID 29420112, PMID 30395902, PMID 31569068, PMID 32058845, PMID 32347302